Drugs / allogeneic umbilical cord blood
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02397018 | May 2015 → Feb 2017 | ischemic stroke | Joanne Kurtzberg, MD | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03473301 | Apr 2018 → Feb 2020 | cerebral palsy | Joanne Kurtzberg, MD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01451528 | Jul 2014 → Dec 2015 | traumatic brain injury | Bundang CHA Hospital | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Umbilical Cord Blood | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01451528 ↗ |
| Known as | AlloCB | “AIM: To evaluate safety and motor function after treatment with allogeneic umbilical cord blood (AlloCB) or umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in...” PMID 35811372 ↗ Jul 2022 |
| Modality | Cell therapy | “Cell therapy like Umbilical cord blood (UCB) transplantation has showed promising results in many animal studies.” NCT01451528 ↗ |
| Route | Intravenous | “Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route” NCT01451528 ↗ |